Selected research
Industry Growth & Trends
Global Central Nervous System (CNS) Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Central Nervous System (CNS) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Central Nervous System (CNS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Central Nervous System (CNS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Central Nervous System (CNS) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Central Nervous System (CNS) Therapeutics market include Biogen, UCB Pharma, Viatris, Eli Lilly, Roche, Merck & Co Inc, Novartis, Johnson and Johnson and Teva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Central Nervous System (CNS) Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Central Nervous System (CNS) Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Central Nervous System (CNS) Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Central Nervous System (CNS) Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Central Nervous System (CNS) Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Central Nervous System (CNS) Therapeutics Market by Company
Biogen
UCB Pharma
Viatris
Eli Lilly
Roche
Merck & Co Inc
Novartis
Johnson and Johnson
Teva
Takeda
Central Nervous System (CNS) Therapeutics Segment by Type
CNS Trauma
Neurovascular Diseases
Neurodegenerative Diseases
Other
Central Nervous System (CNS) Therapeutics Segment by Application
Hospital
Online
Other
Central Nervous System (CNS) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Central Nervous System (CNS) Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- CNS Trauma
- Neurovascular Diseases
- Neurodegenerative Diseases
- Other
Applications
- Hospital
- Online
- Other
Companies covered
- Biogen
- UCB Pharma
- Viatris
- Eli Lilly
- Roche
- Merck & Co Inc
- Novartis
- Johnson and Johnson
- Teva
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Central Nervous System (CNS) Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Central Nervous System (CNS) Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Central Nervous System (CNS) Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Central Nervous System (CNS) Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Central Nervous System (CNS) Therapeutics Market Size (2021-2032)
- 1.5.1 North America Central Nervous System (CNS) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Central Nervous System (CNS) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Central Nervous System (CNS) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size Growth Rate (2021-2032)
2 Central Nervous System (CNS) Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 CNS Trauma
- 2.1.2 Neurovascular Diseases
- 2.1.3 Neurodegenerative Diseases
- 2.1.4 Other
- 2.2 Global Central Nervous System (CNS) Therapeutics Market Size by Type
- 2.2.1 Global Central Nervous System (CNS) Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Central Nervous System (CNS) Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Central Nervous System (CNS) Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Central Nervous System (CNS) Therapeutics Market Size by Regions
- 2.3.1 North America Central Nervous System (CNS) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Central Nervous System (CNS) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Central Nervous System (CNS) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Central Nervous System (CNS) Therapeutics Market Size Breakdown by Type (2021-2026)
3 Central Nervous System (CNS) Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Online
- 3.1.3 Other
- 3.2 Global Central Nervous System (CNS) Therapeutics Market Size by Application
- 3.2.1 Global Central Nervous System (CNS) Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Central Nervous System (CNS) Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Central Nervous System (CNS) Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Central Nervous System (CNS) Therapeutics Market Size by Regions
- 3.3.1 North America Central Nervous System (CNS) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Central Nervous System (CNS) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Central Nervous System (CNS) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Central Nervous System (CNS) Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Central Nervous System (CNS) Therapeutics Industry Trends
- 4.2 Central Nervous System (CNS) Therapeutics Industry Drivers
- 4.3 Central Nervous System (CNS) Therapeutics Industry Opportunities and Challenges
- 4.4 Central Nervous System (CNS) Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Central Nervous System (CNS) Therapeutics Revenue (2021-2026)
- 5.2 Global Central Nervous System (CNS) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Central Nervous System (CNS) Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Central Nervous System (CNS) Therapeutics Company, Product Type & Application
- 5.5 Global Central Nervous System (CNS) Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Central Nervous System (CNS) Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Central Nervous System (CNS) Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Central Nervous System (CNS) Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Biogen
- 6.1.1 Biogen Company Information
- 6.1.2 Biogen Business Overview
- 6.1.3 Biogen Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Biogen Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.1.5 Biogen Recent Developments
- 6.2 UCB Pharma
- 6.2.1 UCB Pharma Company Information
- 6.2.2 UCB Pharma Business Overview
- 6.2.3 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 UCB Pharma Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.2.5 UCB Pharma Recent Developments
- 6.3 Viatris
- 6.3.1 Viatris Company Information
- 6.3.2 Viatris Business Overview
- 6.3.3 Viatris Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Viatris Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.3.5 Viatris Recent Developments
- 6.4 Eli Lilly
- 6.4.1 Eli Lilly Company Information
- 6.4.2 Eli Lilly Business Overview
- 6.4.3 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Eli Lilly Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.4.5 Eli Lilly Recent Developments
- 6.5 Roche
- 6.5.1 Roche Company Information
- 6.5.2 Roche Business Overview
- 6.5.3 Roche Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Roche Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.5.5 Roche Recent Developments
- 6.6 Merck & Co Inc
- 6.6.1 Merck & Co Inc Company Information
- 6.6.2 Merck & Co Inc Business Overview
- 6.6.3 Merck & Co Inc Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.6.5 Merck & Co Inc Recent Developments
- 6.7 Novartis
- 6.7.1 Novartis Company Information
- 6.7.2 Novartis Business Overview
- 6.7.3 Novartis Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Novartis Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.7.5 Novartis Recent Developments
- 6.8 Johnson and Johnson
- 6.8.1 Johnson and Johnson Company Information
- 6.8.2 Johnson and Johnson Business Overview
- 6.8.3 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.8.5 Johnson and Johnson Recent Developments
- 6.9 Teva
- 6.9.1 Teva Company Information
- 6.9.2 Teva Business Overview
- 6.9.3 Teva Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Teva Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.9.5 Teva Recent Developments
- 6.10 Takeda
- 6.10.1 Takeda Company Information
- 6.10.2 Takeda Business Overview
- 6.10.3 Takeda Central Nervous System (CNS) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Takeda Central Nervous System (CNS) Therapeutics Product Portfolio
- 6.10.5 Takeda Recent Developments
7 North America
- 7.1 North America Central Nervous System (CNS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Central Nervous System (CNS) Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Central Nervous System (CNS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Central Nervous System (CNS) Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Central Nervous System (CNS) Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Central Nervous System (CNS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Central Nervous System (CNS) Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Central Nervous System (CNS) Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst